DNA Synthesis Market Intelligence: Size, Share and Growth Outlook Through 2036

Market Overview

Market Size and Outlook

• The DNA synthesis market was valued at USD 3.7 billion in 2025 and is set to reach USD 4.2 billion by 2026-end.
• The market is set to grow at a CAGR of 14.0% between 2026-2036 to reach USD 15.6 billion by 2036.
• Oligonucleotide will dominate with a 47.2% share, while Research And Development will lead with a 54.6% share.
• Biopharmaceutical Companies accounts for 39.8% of End-User demand, with growth supported by expanding clinical applications.

Demand and Growth Drivers

• Clinical adoption and institutional procurement programs are expected to support demand for Oligonucleotide as buyers prioritize compliance and patient outcomes.
• Research And Development demand is expected to remain a growth contributor as regulatory requirements expand during the forecast period.
• EU and South Korea are expected to lead regional growth, supported by healthcare infrastructure expansion and rising institutional spending.

Analyst Perspective

• Brevintel analysis indicates the DNA synthesis market is evolving from a volume-driven category into a segment where clinical differentiation and compliance capabilities define competitive positioning.
• EU is expected to lead growth at 14.2%, driven by healthcare system modernization and institutional capacity expansion.

Market Dynamics

Drivers, Restraints, and Opportunities

• The DNA Synthesis Market faces adoption barriers tied to clinical evidence requirements, institutional procurement cycles, and reimbursement coverage.
• Reimbursement structures in the European Union and the United States create a tiered adoption pattern, where premium products gain traction in tertiary care settings.
• Companies that can scale production while maintaining regulatory compliance and clinical credibility are expected to strengthen their position over the forecast period.

Segmentation Analysis

Service Type Outlook

• Oligonucleotide is expected to account for 47.2% of the Service Type segment, supported by established procurement patterns and specification requirements.

Application and End User Outlook

• Research And Development is expected to hold 54.6% of Application demand, reflecting clinical preference and institutional standards.
• Biopharmaceutical Companies accounts for 39.8% of End-User demand, with growth supported by expanding clinical applications.

Regional Outlook

EU, South Korea, and the United States

• EU is expected to lead growth at 14.2%, driven by healthcare system modernization and institutional capacity expansion.
• The United States and the European Union are expected to maintain significant market share, supported by established institutional procurement and regulatory frameworks.
• EU and South Korea represent the strongest growth trajectories through 2036, with demand supported by public healthcare investment and private sector expansion.

Competitive Landscape

Overview

• Integrated DNA Technologies, GenScript Biotech Corporation, Eurofins Genomics, and Twist Bioscience compete across oligonucleotide synthesis and gene-scale services.
• Synthetic Genomics, BioBasic Inc., LGC Biosearch Technologies, DNA2.0, ATDBio Ltd., Bioneer Corporation, Jena Bioscience GmbH, Roche Diagnostics, and Pacific Biosciences compete in specialty synthesis and sequencing-adjacent platforms.

Key Players

Integrated Producers

• Integrated DNA Technologies
• GenScript Biotech Corporation
• Eurofins Genomics
• Twist Bioscience
• Roche Diagnostics
• Pacific Biosciences

Specialty Suppliers

• Synthetic Genomics
• BioBasic Inc.
• LGC Biosearch Technologies
• DNA2.0
• ATDBio Ltd.
• Bioneer Corporation
• Jena Bioscience GmbH